Overview: LPL Breast Cancer Panel TestIntroduction: The LPL Breast Cancer Panel Test analyzes breast cancer markers to diagnose breast cancer, causing lumps or pain. Following 2023 NCCN guidelines, it uses histopathology for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected breast cancer.
Other Names: Breast Cancer IHC Panel, Breast Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Breast cancer panel testing began in the 1990s with immunohistochemistry research. Marker panels improved in the 2000s, enhancing diagnostic precision.
Purpose: Analyzes breast cancer markers to diagnose breast cancer, guides treatment, and evaluates patients with lumps or pain.
Test Parameters: 1. Breast Cancer Markers
Pretest Condition: No fasting required. Collect tissue. Report history of lumps, pain, or breast cancer symptoms.
Specimen: Tissue (FFPE, 0.5-2 cma³). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lumps, pain, nipple discharge, or family history of breast cancer. Include current medications, especially hormonal therapies.
Consent: Written consent required, detailing the tests purpose, breast cancer implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to analyze breast cancer markers (e.g., ER, PR, HER2) in tissue. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for breast cancer diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or low tissue quality can affect results. Contamination may reduce specificity.
Clinical Significance: Positive markers confirm breast cancer subtype, guiding targeted therapy (e.g., trastuzumab for HER2-positive). Negative results may require further testing.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: BRCA mutation testing, mammogram, or breast MRI to confirm breast cancer diagnosis.
Test Limitations: Not specific to one breast cancer subtype; clinical correlation is needed. Invasive biopsy carries risks.
References: NCCN Breast Cancer Guidelines, 2023; Journal of Clinical Oncology, Gradishar WJ, 2022.
